Business

VOLUNTARY ANNOUNCEMENT FIRST PATIENT ENROLLED IN PHASE III CLINICAL TRIAL OF ANAPRAZOLE SODIUM FOR HELICOBACTER PYLORI ERADICATION

VOLUNTARY ANNOUNCEMENT FIRST PATIENT ENROLLED IN PHASE III CLINICAL TRIAL OF ANAPRAZOLE SODIUM FOR HELICOBACTER PYLORI ERADICATION

articleXuanzhu Biopharmaceutical Co., Ltd. Class HJune 21, 20263/news/voluntary-announcement-first-patient-enrolled-in-phase-iii-clinical-trial-of-anaprazole-sodium-for-helicobacter-pylori-eradication
VOLUNTARY ANNOUNCEMENT FIRST PATIENT ENROLLED IN PHASE III CLINICAL TRIAL OF ANAPRAZOLE SODIUM FOR HELICOBACTER PYLORI ERADICATION

About this update from Xuanzhu Biopharmaceutical Co., Ltd. Class H

Xuanzhu Biopharmaceutical Co., Ltd. Class H (2575) Press ReleaseView Attachment

View stock analysis, news, and events for Xuanzhu Biopharmaceutical Co., Ltd. Class H